SCHEMBL14749351

SCHEMBL14749351

Cc1noc(C)c1CC(=O)N1CCCC(c2cc(-c3ccc(F)cc3)nn2-c2ncccn2)C1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 5/20 0.54
▸ LMNA P02545 5/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ PKM P14618 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ RORC P51449 1/20 0.37
▸ TSHR P16473 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ GRM5 P41594 1/20 0.37
▸ CLPP Q16740 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14749319 0.85 PRCP (0.57) PRCPKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL14749316 0.85 PRCP (0.57) PRCPLMNAKDM4EALDH1A1MAPK1
SCHEMBL14749333 0.83 PRCP (0.59) PRCPKDM4EALDH1A1MAPK1KMT2A
SCHEMBL14749330 0.82 PRCP (0.57) PRCPALDH1A1SMN1; SMN2GRM5
SCHEMBL14749326 0.81 PRCP (0.55) PRCPALDH1A1SMN1; SMN2GRM5
SCHEMBL14749335 0.81 PRCP (0.64) PRCPKDM4EALDH1A1KMT2AMAPT
SCHEMBL14749328 0.81 PRCP (0.61) PRCPALDH1A1SMN1; SMN2MAPTGRM5
SCHEMBL14749338 0.81 PRCP (0.65) PRCPKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL12184060 0.81 PRCP (0.53) PRCPKDM4EALDH1A1SMN1; SMN2GRM5
SCHEMBL14749332 0.80 PRCP (0.54) PRCPKDM4EALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059830-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885LMNA 3736/4885KDM4E 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback